Planning a radiolabeled drug development program takes more than just access to radioisotopes. It requires deep expertise in radiosynthetic chemistry, metabolism, and pharmacokinetics (PK).
Pharmaron has a proven track record of supporting radiolabeled metabolism studies across both preclinical and clinical stages. Its fully integrated services for small molecules and biologics combine advanced radioisotopic capabilities with DMPK expertise, helping customers generate the high-quality ADME data needed to move their program forward with confidence.
With critical study endpoints and regulatory expectations to meet, you need a partner who understands the science and the strategy behind radiolabelled development.
Learn more about how Pharmaron can support your entire radiolabeled drug development program, from radiosynthesis through to nonclinical and clinical studies.
About Pharmaron
Pharmaron is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.